Navigation Links
MetaStat to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22, 2013
Date:1/18/2013

MONTCLAIR, N.J., Jan. 18, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), ("MetaStat" or the "Company"), a life science company focused on understanding and treating systemic metastasis, today announced that the Company will be presenting at the NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference held at the Hard Rock Hotel & Casino, Hollywood, Florida, on Tuesday, January 22, 2013 at 4:30 p.m. Eastern Time.  Dr. Oscar Bronsther , Chief Executive Officer and Chief Medical Officer, will host the presentation.

A live audio and high-definition video webcast of MetaStat's presentation and a copy of the presentation materials will be available on the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/nine/home.htm.

About MetaStat, Inc.
MetaStat's proprietary platform technologies are the result of over 15 years of collaboration involving four scientific/academic institutions, which enabled us to characterize the behavior, mechanics and genetics of metastatic cancer cells.

Our MetaSite Breast™ and MenaCalc™ diagnostic product lines are designed to accurately predict the probability of cancer metastasizing. They are intended to allow clinicians to better "customize" cancer treatment decisions by positively identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies. Furthermore, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid epithelial cancers, including breast, prostate, lung and colorectal, which account for over 50% of all new cancer cases in the U.S. each year. As such, we believe our diagnostic prod
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
2. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
3. MetaStat, Inc. Announces Allowance of Patent Claims
4. Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.
5. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
6. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... - Two Milestones Reached in Zonisamide Patent Portfolio ... Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... nervous system-related disorders, today,announced the initiation of its ... formulation of zonisamide plus olanzapine.,The Phase 2a clinical ...
... 2 Clarient, Inc.,(Nasdaq: CLRT ), a ... pathologists, oncologists and the pharmaceutical industry,today announced that ... an,exclusive interview on WallSt.net,s 3-Minute Press Show., ... company, and the,significance of the company,s latest press ...
... Zevalin only Radioimmunotherapy in U.S. to be Indicated ... for Use ... Inc. (CTI),(Nasdaq and MTA: CTIC) announced today that it has ... and Drug,Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation ...
Cached Biology Technology:Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 2Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 3Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain 4[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:4/23/2014)... Valley, NY. (Apr. 23, 2014) People who have ... potential to restore neurological function. However, a study conducted ... issue of Cell Transplantation , but is currently ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group ... cells (PBSCs) injected directly into the brain and a ...
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... may begin in the womb, researchers from Tel Aviv University ... twin can compromise the health of his twin sister before ... published in the journal Pediatrics, the researchers analyzed the incidence ... twins. When born premature, girls who share the womb with ...
... A recent University of Iowa study reveals a biological link ... women than men are diagnosed with chronic pain and fatigue ... mice, the researchers, led by Kathleen Sluka, Ph.D., professor in ... the UI Roy J. and Lucille A. Carver College of ...
... 2008 The Global Innovation Imperatives (Gii) project ... their first session at the American Chemical Societys ... a joint collaboration between the ACS Committee on ... seeks to combat worldwide health, environmental and societal ...
Cached Biology News:War between the sexes begins before twins' birth, TAU researchers say 2U. Iowa study finds biological link between pain and fatigue 2At ACS' national meeting, global initiative set to tackle water issues 2
... 10 ,Yeast extract, 5 ,Sodium chloride, ... ammonium citrate, 0.5 ,IPTG, 0.03 ... autoclavable chromogenic substrate for -galactosidase. The ... generates a black insoluble precipitate. Lac+ ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
Biology Products: